Aliases & Classifications for Vascular Dementia

MalaCards integrated aliases for Vascular Dementia:

Name: Vascular Dementia 12 15 17
Multi-Infarct Dementia 77 55 74
Dementia, Vascular 77 45 74
Dementia, Vascular, Susceptibility to 13
Vascular Dementia, Susceptibility to 6
Dementia, Multi-Infarct 45
Multi Infarct Dementia 12
Multifocal Dementia 12
Dementia Vascular 56

Classifications:



External Ids:

Disease Ontology 12 DOID:8725
ICD9CM 36 290.4
SNOMED-CT 69 56267009
ICD10 34 F01 F01.1 F01.5

Summaries for Vascular Dementia

NINDS : 55 Multi-infarct dementia (MID) is a common cause of memory loss in the elderly.  MID is caused by multiple strokes (disruption of blood flow to the brain).  Disruption of blood flow leads to damaged brain tissue.  Some of these strokes may occur without noticeable clinical symptoms. Doctors refer to these as “silent strokes.”  An individual having a silent stroke may not even know it is happening, but over time, as more areas of the brain are damaged and more small blood vessels are blocked, the symptoms of MID begin to appear.  MID can be diagnosed by an MRI or CT of the brain, along with a neurological examination. Symptoms include confusion or problems with short-term memory; wandering, or getting lost in familiar places; walking with rapid, shuffling steps; losing bladder or bowel control; laughing or crying inappropriately; having difficulty following instructions; and having problems counting money and making monetary transactions.  MID, which typically begins between the ages of 60 and 75, affects men more often than women. Because the symptoms of MID are so similar to Alzheimer’s disease, it can be difficult for a doctor to make a firm diagnosis.  Since the diseases often occur together, making a single diagnosis of one or the other is even more problematic. 

MalaCards based summary : Vascular Dementia, also known as multi-infarct dementia, is related to binswanger's disease and dementia. An important gene associated with Vascular Dementia is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Selenium Micronutrient Network and Neuroscience. The drugs Citalopram and Memantine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are homeostasis/metabolism and behavior/neurological

Disease Ontology : 12 A dementia that involves impairments in cognitive function caused by problems in blood vessels that feed the brain.

Wikipedia : 77 Vascular dementia, also known as multi-infarct dementia (MID) and vascular cognitive impairment (VCI),... more...

Related Diseases for Vascular Dementia

Diseases related to Vascular Dementia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 136)
# Related Disease Score Top Affiliating Genes
1 binswanger's disease 32.0 ACHE APOE APP MAPT NOTCH3
2 dementia 31.4 ACHE APOE APP BCHE CHAT MAPT
3 alzheimer disease 30.8 ACHE APOE APP BCHE CHAT CST3
4 vascular disease 30.7 APOE CST3 MTHFR PON1 TNF VEGFA
5 atherosclerosis susceptibility 30.2 APOE PON1 TNF
6 frontotemporal dementia 30.0 ACHE APOE APP MAPT PSEN1
7 carotid stenosis 30.0 APOE MTHFR TNF
8 head injury 29.8 APOE CHAT
9 cerebrovascular disease 29.7 ACHE APOE APP MAPT MTHFR NOTCH3
10 arteries, anomalies of 29.6 APOE PON1 TNF VEGFA
11 hydrocephalus 29.6 APOE APP MAPT MBP
12 brain injury 29.4 APOE MAPT MBP
13 dementia, lewy body 29.4 ACHE APOE APP BCHE MAPT PSEN1
14 cerebral amyloid angiopathy, cst3-related 29.3 APOE APP CST3 MAPT PSEN1 SERPINA3
15 heart disease 29.1 APOE CST3 MTHFR PON1 TNF VEGFA
16 alzheimer disease 2 28.9 APOE APP BCHE MAPT PSEN1 SERPINA3
17 myocardial infarction 28.9 APOE CST3 MTHFR PON1 TNF VEGFA
18 subcortical arteriosclerotic encephalopathy 11.2
19 cerebral arteriosclerosis 11.2
20 dementia - subcortical 11.0
21 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 10.9
22 dementia pugilistica 10.5
23 simultanagnosia 10.4 APOE MAPT
24 posterior cortical atrophy 10.4 APOE MAPT
25 depression 10.4
26 aging 10.4
27 cerebral arteriopathy, autosomal recessive, with subcortical infarcts and leukoencephalopathy 10.3
28 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2 10.3
29 nominal aphasia 10.3 MAPT PSEN1
30 alzheimer's disease 1 10.3 APOE APP
31 alzheimer disease 4 10.3 APOE PSEN1
32 progressive non-fluent aphasia 10.3 MAPT PSEN1
33 butyrylcholinesterase deficiency 10.3 ACHE BCHE
34 dural sinus malformation 10.3
35 behavioral variant of frontotemporal dementia 10.3 MAPT PSEN1
36 ischemic heart disease 10.3 APOE MTHFR TNF
37 cerebral atherosclerosis 10.3 APOE MTHFR
38 cerebral palsy 10.3 APOE MTHFR TNF
39 hemifacial spasm 10.3 MTHFR VEGFA
40 semantic dementia 10.2 APOE MAPT PSEN1
41 critical limb ischemia 10.2 TNF VEGFA
42 early-onset, autosomal dominant alzheimer disease 10.2 APP PSEN1
43 alzheimer disease mitochondrial 10.2 APOE APP MAPT
44 kashin-beck disease 10.2 TNF VEGFA
45 speech and communication disorders 10.2 APOE MAPT PSEN1
46 gait apraxia 10.2 APOE APP PSEN1
47 inclusion body myositis 10.2 APOE APP MAPT
48 hereditary cerebral amyloid angiopathy 10.2 APP CST3
49 senile plaque formation 10.2 APOE APP CHAT
50 kluver-bucy syndrome 10.2 APP MAPT PSEN1

Comorbidity relations with Vascular Dementia via Phenotypic Disease Network (PDN):


Acute Cystitis Cerebral Atherosclerosis
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Vascular Dementia:



Diseases related to Vascular Dementia

Symptoms & Phenotypes for Vascular Dementia

MGI Mouse Phenotypes related to Vascular Dementia:

47 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.34 ACHE APOE APP BCHE CHAT CST3
2 behavior/neurological MP:0005386 10.33 ACHE APOE APP CHAT MAPT MBP
3 growth/size/body region MP:0005378 10.26 ACHE APOE APP CHAT MAPT MBP
4 mortality/aging MP:0010768 10.25 ACHE APOE APP BCHE CHAT CST3
5 cardiovascular system MP:0005385 10.24 APOE APP CHAT CST3 MAPT NOTCH3
6 nervous system MP:0003631 10.21 ACHE APOE APP CHAT CST3 MAPT
7 hematopoietic system MP:0005397 10.16 ACHE APOE APP MAPT MBP NOTCH3
8 integument MP:0010771 10.13 APOE APP MAPT MTHFR NOTCH3 PSEN1
9 muscle MP:0005369 10.1 ACHE APOE APP CHAT CST3 MAPT
10 limbs/digits/tail MP:0005371 9.93 APOE CHAT MTHFR PSEN1 TNF VEGFA
11 reproductive system MP:0005389 9.93 ACHE APOE APP BCHE CHAT CST3
12 no phenotypic analysis MP:0003012 9.87 ACHE APOE APP MAPT MTHFR TNF
13 normal MP:0002873 9.86 APP CHAT MAPT MBP NEFL NOTCH3
14 respiratory system MP:0005388 9.5 ACHE APOE CHAT NOTCH3 PSEN1 TNF
15 vision/eye MP:0005391 9.32 ACHE APOE CHAT MAPT MBP MTHFR

Drugs & Therapeutics for Vascular Dementia

Drugs for Vascular Dementia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 190)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4 59729-33-8 2771
2
Memantine Approved, Investigational Phase 4,Not Applicable 19982-08-2 4054
3
Dopamine Approved Phase 4,Phase 2,Phase 3,Not Applicable 62-31-7, 51-61-6 681
4
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
5
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1 120014-06-4 3152
6
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
7
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
8
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
9
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
10
Calcium Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable 7440-70-2 271
11
Corticosterone Experimental Phase 4 50-22-6 5753
12 Parasympatholytics Phase 4
13 Antidepressive Agents Phase 4,Phase 3
14 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3
15 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
16 Antiparkinson Agents Phase 4,Phase 3,Not Applicable
17 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
18 Cholinergic Antagonists Phase 4
19 Antidepressive Agents, Second-Generation Phase 4
20 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
21 Psychotropic Drugs Phase 4,Phase 3,Phase 2
22 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
23 Serotonin Agents Phase 4,Phase 3
24 Serotonin Uptake Inhibitors Phase 4
25 Muscarinic Antagonists Phase 4
26 Excitatory Amino Acids Phase 4,Not Applicable
27 Excitatory Amino Acid Antagonists Phase 4,Not Applicable
28 Dopamine Agents Phase 4,Phase 2,Phase 3,Not Applicable
29 Vasodilator Agents Phase 4,Phase 2,Phase 3,Not Applicable
30 Hormones Phase 4,Phase 2,Phase 3,Not Applicable
31 calcium channel blockers Phase 4,Phase 2,Phase 3,Not Applicable
32 Antihypertensive Agents Phase 4,Phase 2,Phase 3,Not Applicable
33 Calcium, Dietary Phase 4,Phase 2,Phase 3,Not Applicable
34 Cholinesterase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Nootropic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
36 Phosphodiesterase Inhibitors Phase 4,Phase 2
37 Cyclooxygenase Inhibitors Phase 4
38 Anti-Asthmatic Agents Phase 4
39 Anti-Inflammatory Agents, Non-Steroidal Phase 4
40 Antipyretics Phase 4,Phase 2
41 Fibrinolytic Agents Phase 4
42 Anti-Inflammatory Agents Phase 4
43 Analgesics, Non-Narcotic Phase 4,Phase 2
44 Protective Agents Phase 4,Phase 3
45 Antirheumatic Agents Phase 4
46 Neuroprotective Agents Phase 4,Phase 3
47 Platelet Aggregation Inhibitors Phase 4,Phase 3
48 Respiratory System Agents Phase 4
49 Analgesics Phase 4,Phase 2
50 Bronchodilator Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 122)
# Name Status NCT ID Phase Drugs
1 Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
2 Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial Unknown status NCT00196703 Phase 4 memantine
3 Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
4 Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia Completed NCT00165763 Phase 4 donepezil hydrochloride (Aricept)
5 Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions Completed NCT00847860 Phase 4 Cilostazol;Aspirin
6 A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Completed NCT00947531 Phase 4 Cerebrolysin;0.9% Saline Solution
7 Memantine and Intensive Speech-Language Therapy in Aphasia Completed NCT00640198 Phase 4 memantine;memantine;placebo
8 Efficacy of Pain Treatment on Depression in Patients With Dementia Completed NCT02267057 Phase 4 Paracetamol;Buprenorphine;Paracetamol placebo;Buprenorphine placebo
9 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
10 Symptomatic Treatment of Vascular Cognitive Impairment Unknown status NCT02098824 Phase 2, Phase 3 Galantamine;Methylphenidate;Placebo
11 Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia Completed NCT02453932 Phase 3 Tianzhi granule and placebo identified to donepezil;Donepezil and placebo identified to Tianzhi granule;Placebo
12 Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed NCT00130338 Phase 3 Rivastigmine
13 Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed NCT00099216 Phase 3 Rivastigmine
14 A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia Completed NCT00261573 Phase 3 galantamine hydrobromide
15 A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia Completed NCT00035191 Phase 3 galantamine
16 Seroquel- Agitation Associated With Dementia Completed NCT00621647 Phase 3 Quetiapine Fumarate;Quetiapine Fumarate;Placebo
17 A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia Completed NCT00249158 Phase 3 Risperidone
18 Combination of Metformine/Inulin Versus Metformin on Prostate Benign Hyperplasia in Metabolic Syndrome Completed NCT02778776 Phase 3 Metformin
19 Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia Completed NCT00209456 Phase 3 DatSCAN
20 A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia Completed NCT00249145 Phase 3 risperidone
21 A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia Completed NCT00253123 Phase 3 risperidone
22 Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type Recruiting NCT03721705 Phase 3
23 Risk Reduction for Alzheimer's Disease Recruiting NCT02913664 Phase 2, Phase 3 Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine);Atorvastatin
24 The Healthy Patterns Study Recruiting NCT03682185 Phase 3
25 Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis Recruiting NCT03325556 Phase 3 Placebo;Pimavanserin 34 mg;Pimavanserin 20 mg
26 Effects of Amlodipine and Other Blood Pressure Lowering Agents on Microvascular Function Recruiting NCT03082014 Phase 3 Amlodipine;Losartan;Atenolol
27 MIND Diet Intervention and Cognitive Decline Active, not recruiting NCT02817074 Phase 3
28 Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia Not yet recruiting NCT03804229 Phase 3 Butylphthalide soft capsule;Placebo soft capsule
29 The Clinical Trial of Chinese Herbal Medicine (SaiLuoTong) Capsule Not yet recruiting NCT03789760 Phase 3 SaiLuoTong capsule;placebo
30 The Clinical Trial of Chinese Herbal Medicine SaiLuoTong Capsule Unknown status NCT01978730 Phase 2 high dose group of SaiLuoTong capsule;low dose group of SaiLuoTong;the control group
31 Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity Unknown status NCT01466543 Phase 2 Zydena (Udenafil);Placebo
32 Safety Study of Dabigatran in CADASIL Unknown status NCT01361763 Phase 2 Dabigatran;Antiplatelets
33 Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia Completed NCT01761227 Phase 2 Fufangdanshen Tablets;Placebo
34 Study of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency) Completed NCT01475578 Phase 2 STA-1;Ergoloid Mesylates tablet
35 Effect of Insulin Sensitizer Metformin on AD Biomarkers Completed NCT01965756 Phase 2 Metformin;Placebos
36 DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia Completed NCT02103673 Phase 2 DAOIB;Placebo
37 Oxidative Stress and Nutritional Supplementation Intervention Study Completed NCT01234506 Phase 2
38 Delta-THC in Dementia Completed NCT01608217 Phase 2 delta-9-tetrahydrocannabinol (delta-THC);Placebo;Acetaminophen;Acetaminophen
39 The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment Completed NCT00103948 Phase 2 Aricept
40 Efficacy and Safety of TMBCZG in Mild to Moderate Vascular Dementia Recruiting NCT03230071 Phase 2 TMBCZG
41 A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia Recruiting NCT02886494 Phase 2 BAC;Matched placebo
42 Efficacy and Safety of MMFS in Mild AD Recruiting NCT03531684 Phase 2
43 n-3 PUFA for Vascular Cognitive Aging Active, not recruiting NCT01953705 Phase 2 Omega 3 PUFA;Placebo
44 BAC in Patient With Alzheimer's Disease or Vascular Dementia Not yet recruiting NCT02467413 Phase 2 BAC
45 Aricept to Improve Functional Tasks in Vascular Dementia Active, not recruiting NCT00457769 Phase 1 Donepezil and self-generated memory training;Donepezil and experimenter-administered memory training
46 Managing Vascular Dementia Risk Factors With SymTrend Not yet recruiting NCT03702543 Phase 1
47 Remote Ischemic Preconditioning for Subcortical Vascular Dementia Unknown status NCT03022149 Not Applicable
48 Blood-brain Barrier Leakage in Dementia. A Dynamic Contrast-enhanced MRI Study Unknown status NCT02018913
49 Hyperbaric Oxygen Therapy for Mild Cognitive Impairment Unknown status NCT02085330 Not Applicable
50 MRS and DTI of White Matter in Alzheimer's Disease Unknown status NCT00172900

Search NIH Clinical Center for Vascular Dementia

Cochrane evidence based reviews: dementia, vascular

Genetic Tests for Vascular Dementia

Anatomical Context for Vascular Dementia

MalaCards organs/tissues related to Vascular Dementia:

42
Brain, Testes, Cortex, Endothelial, Temporal Lobe, Eye, Bone

Publications for Vascular Dementia

Articles related to Vascular Dementia:

(show top 50) (show all 1992)
# Title Authors Year
1
Discovery of potent, selective, and orally bioavailable inhibitors against phosphodiesterase-9, a novel target for the treatment of vascular dementia. ( 30916555 )
2019
2
Naomaitai Ameliorated Brain Damage in Rats with Vascular Dementia by PI3K/PDK1/AKT Signaling Pathway. ( 30867669 )
2019
3
Association of Chronic Periodontitis on Alzheimer's Disease or Vascular Dementia. ( 30874308 )
2019
4
Emerging molecular mechanisms of vascular dementia. ( 30883434 )
2019
5
Glycyrrhizic acid renders robust neuroprotection in rodent model of vascular dementia by controlling oxidative stress and curtailing cytochrome-c release. ( 30794076 )
2019
6
Ginsenoside compound K attenuates cognitive deficits in vascular dementia rats by reducing the Aβ deposition. ( 30799178 )
2019
7
Attenuation of hyperhomocysteinemia induced vascular dementia by sodium orthovanadate perhaps via PTP1B: pertinent downstream outcomes. ( 30721761 )
2019
8
N-homocysteinylation of tau and MAP1 is increased in autopsy specimens of Alzheimer's disease and vascular dementia. ( 30734924 )
2019
9
COWAT Performance of Persons With Alzheimer's Dementia, Vascular Dementia, and Parkinson's Disease Dementia According to Stage of Cognitive Impairment. ( 30746867 )
2019
10
Hwangryunhaedok-Tang Exerts Neuropreventive Effect on Memory Impairment by Reducing Cholinergic System Dysfunction and Inflammatory Response in a Vascular Dementia Rat Model. ( 30669383 )
2019
11
Ameliorative effect of Phosphodiesterase-5 inhibitor in Rat model of Vascular Dementia. ( 30706814 )
2019
12
Chotosan ameliorates cognitive impairment and hippocampus neuronal loss in experimental vascular dementia via activating the Nrf2-mediated antioxidant pathway. ( 30642751 )
2019
13
N-Palmitoylethanolamine-oxazoline (PEA-OXA): A new therapeutic strategy to reduce neuroinflammation, oxidative stress associated to vascular dementia in an experimental model of repeated bilateral common carotid arteries occlusion. ( 30660740 )
2019
14
Memory for Serial Order in Alzheimer's Disease and Vascular Dementia: A Competitive Queuing Analysis. ( 29566139 )
2019
15
A mouse model of subcortical vascular dementia reflecting degeneration of cerebral white matter and microcirculation. ( 29053032 )
2019
16
Vascular dementia: clinicopathologic and genetic considerations. ( 29380913 )
2018
17
Predicting outcome of Morris water maze test in vascular dementia mouse model with deep learning. ( 29415035 )
2018
18
Chinese Herbal Medicine for Vascular Dementia: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials. ( 29439346 )
2018
19
Genomea89wide DNA methylation profiling in a rat model with vascular dementia. ( 29749552 )
2018
20
Betulinic acid, a natural PDE inhibitor restores hippocampal cAMP/cGMP and BDNF, improve cerebral blood flow and recover memory deficits in permanent BCCAO induced vascular dementia in rats. ( 29778746 )
2018
21
Stroke Risk and Vascular Dementia in South Asians. ( 29974259 )
2018
22
Potential of carnosine, a histamine precursor in rat model of bilateral common carotid artery occlusion-induced vascular dementia. ( 29676814 )
2018
23
Sleep Apnea Is a Risk Factor for Stroke and Vascular Dementia. ( 29938308 )
2018
24
The involvement of neuroinflammation and necroptosis in the hippocampus during vascular dementia. ( 29759140 )
2018
25
Distinct Patterns of Rich Club Organization in Alzheimer's Disease and Subcortical Vascular Dementia: A White Matter Network Study. ( 29710719 )
2018
26
FoxO1-mediated autophagy plays an important role in the neuroprotective effects of hydrogen in a rat model of vascular dementia. ( 29885845 )
2018
27
Neuroprotective effect of berberine chloride on cognitive impairment and hippocampal damage in experimental model of vascular dementia. ( 29372037 )
2018
28
Lower Plasma Klotho Concentrations Are Associated with Vascular Dementia but Not Late-Onset Alzheimer's Disease. ( 29768278 )
2018
29
Factors associated with type 2 diabetes in patients with vascular dementia: a population-based cross-sectional study. ( 29973163 )
2018
30
<i>Panax ginseng</i> extract attenuates neuronal injury and cognitive deficits in rats with vascular dementia induced by chronic cerebral hypoperfusion. ( 29722318 )
2018
31
Herbal medicine as a promising therapeutic approach for the management of vascular dementia: A systematic literature review. ( 29786916 )
2018
32
Tau pathology and neurochemical changes associated with memory dysfunction in an optimised murine model of global cerebral ischaemia - A potential model for vascular dementia? ( 29649504 )
2018
33
Molecular Pharmacology of Rosmarinic and Salvianolic Acids: Potential Seeds for Alzheimer's and Vascular Dementia Drugs. ( 29401682 )
2018
34
Albuminuria Increases the Risks for Both Alzheimer Disease and Vascular Dementia in Community-Dwelling Japanese Elderly: The Hisayama Study. ( 29353232 )
2018
35
Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. ( 29933741 )
2018
36
Repeated administration of Sailuotong, a fixed combination of Panax ginseng, Ginkgo biloba, and Crocus sativus extracts for vascular dementia, alters CYP450 activities in rats. ( 29425645 )
2018
37
Acupuncture Prevents the Impairment of Hippocampal LTP Through I^1-AR in Vascular Dementia Rats. ( 29435917 )
2018
38
Diagnostic relevance of spatial orientation for vascular dementia: A case study. ( 29682239 )
2018
39
Neuropsychiatric symptoms in vascular dementia: Epidemiologic and clinical aspects. ( 29682232 )
2018
40
Ligustrazine suppresses neuron apoptosis via the Bax/Bcl-2 and caspase-3 pathway in PC12 cells and in rats with vascular dementia. ( 29247598 )
2018
41
Specific Patterns of White Matter Alterations Help Distinguishing Alzheimer's and Vascular Dementia. ( 29922120 )
2018
42
Intermittent streptozotocin administration induces behavioral and pathological features relevant to Alzheimer's disease and vascular dementia. ( 29738850 )
2018
43
Efficacy and safety of the compound Chinese medicine SaiLuoTong inA vascular dementia: A randomized clinical trial. ( 29955654 )
2018
44
Puerarin up-regulates methyl-CpG binding protein 2 phosphorylation in hippocampus of vascular dementia rats. ( 29327124 )
2018
45
Nanotherapy for Alzheimer's disease and vascular dementia: Targeting senile endothelium. ( 29274774 )
2018
46
Mitochondrial factor and cell cytokines associate with TCM syndrome scale in vascular dementia patients. ( 29375680 )
2018
47
The potential protective effects of cannabinoid receptor agonist WIN55,212-2 on cognitive dysfunction is associated with the suppression of autophagy and inflammation in an experimental model of vascular dementia. ( 29945070 )
2018
48
Effect of Telmisartan on Preventing Learning and Memory Deficits Via Peroxisome Proliferator-Activated Receptor-I^ in Vascular Dementia Spontaneously Hypertensive Rats. ( 29241675 )
2018
49
Cognitive impairment in Parkinson's disease, Alzheimer's dementia, and vascular dementia: the role of the clock-drawing test. ( 29417704 )
2018
50
Aging and cerebrovascular lesions in pure and in mixed neurodegenerative and vascular dementia brains: a neuropathological study. ( 30509027 )
2018

Variations for Vascular Dementia

ClinVar genetic disease variations for Vascular Dementia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 TNF NM_000594.3(TNF): c.-1037C> T single nucleotide variant risk factor rs1799724 GRCh37 Chromosome 6, 31542482: 31542482
2 TNF NM_000594.3(TNF): c.-1037C> T single nucleotide variant risk factor rs1799724 GRCh38 Chromosome 6, 31574705: 31574705

Expression for Vascular Dementia

Search GEO for disease gene expression data for Vascular Dementia.

Pathways for Vascular Dementia

GO Terms for Vascular Dementia

Cellular components related to Vascular Dementia according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.85 APP MAPT NEFL PSEN1
2 endoplasmic reticulum lumen GO:0005788 9.83 APOE APP BCHE CST3
3 extracellular space GO:0005615 9.81 ACHE APOE APP BCHE CST3 PON1
4 membrane raft GO:0045121 9.8 APP MAPT PSEN1 TNF
5 neuron projection GO:0043005 9.8 APP CHAT MAPT NEFL PSEN1
6 cell surface GO:0009986 9.8 ACHE APP MBP PSEN1 TNF VEGFA
7 blood microparticle GO:0072562 9.67 APOE BCHE PON1 SERPINA3
8 platelet alpha granule lumen GO:0031093 9.63 APP SERPINA3 VEGFA
9 growth cone GO:0030426 9.56 APP MAPT NEFL PSEN1
10 synaptic cleft GO:0043083 9.54 ACHE APOE
11 ciliary rootlet GO:0035253 9.51 APP PSEN1
12 nuclear envelope lumen GO:0005641 9.48 APP BCHE
13 main axon GO:0044304 9.43 APP MAPT
14 extracellular region GO:0005576 9.36 ACHE APOE APP BCHE CST3 MAPT
15 neuromuscular junction GO:0031594 9.26 ACHE APP NEFL PSEN1

Biological processes related to Vascular Dementia according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.85 APOE APP CST3 PSEN1
2 response to oxidative stress GO:0006979 9.84 APOE APP PSEN1
3 platelet degranulation GO:0002576 9.83 APP SERPINA3 VEGFA
4 negative regulation of peptidase activity GO:0010466 9.83 APP CST3 SERPINA3
5 Notch signaling pathway GO:0007219 9.83 APP NOTCH3 PSEN1
6 positive regulation of protein phosphorylation GO:0001934 9.81 APP PSEN1 TNF VEGFA
7 response to toxic substance GO:0009636 9.8 MBP NEFL PON1
8 cholesterol metabolic process GO:0008203 9.79 APOE APP PON1
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.79 APP TNF VEGFA
10 forebrain development GO:0030900 9.75 APP NOTCH3 PSEN1
11 negative regulation of neuron apoptotic process GO:0043524 9.73 APOE NEFL PSEN1 RETREG1
12 negative regulation of gene expression GO:0010629 9.72 APOE APP MAPT TNF VEGFA
13 positive regulation of MAP kinase activity GO:0043406 9.7 PSEN1 TNF VEGFA
14 response to lead ion GO:0010288 9.67 APP MAPT
15 microglial cell activation GO:0001774 9.66 MAPT TNF
16 axon development GO:0061564 9.65 MAPT NEFL
17 synapse organization GO:0050808 9.65 APP MAPT PSEN1
18 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.64 APOE TNF
19 positive regulation of cholesterol efflux GO:0010875 9.64 APOE PON1
20 neurotransmitter biosynthetic process GO:0042136 9.63 ACHE CHAT
21 supramolecular fiber organization GO:0097435 9.62 CST3 MAPT
22 negative regulation of long-term synaptic potentiation GO:1900272 9.61 APOE APP
23 neuron projection maintenance GO:1990535 9.6 APP PSEN1
24 amyloid fibril formation GO:1990000 9.59 APP MAPT
25 axonal transport of mitochondrion GO:0019896 9.58 MAPT NEFL
26 locomotion GO:0040011 9.57 NEFL PSEN1
27 response to folic acid GO:0051593 9.56 BCHE MTHFR
28 modulation of age-related behavioral decline GO:0090647 9.54 APP PSEN1
29 negative regulation of low-density lipoprotein receptor activity GO:1905598 9.49 APP PSEN1
30 regulation of epidermal growth factor-activated receptor activity GO:0007176 9.46 APP PSEN1
31 artery morphogenesis GO:0048844 9.43 APOE NOTCH3 VEGFA
32 astrocyte activation involved in immune response GO:0002265 9.4 APP PSEN1
33 smooth endoplasmic reticulum calcium ion homeostasis GO:0051563 9.37 APP PSEN1
34 amyloid precursor protein metabolic process GO:0042982 9.33 ACHE APOE PSEN1
35 positive regulation of amyloid fibril formation GO:1905908 9.13 APOE APP PSEN1
36 astrocyte activation GO:0048143 8.92 APP MAPT PSEN1 TNF

Molecular functions related to Vascular Dementia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.73 APP BCHE MAPT NOTCH3
2 peptidase inhibitor activity GO:0030414 9.58 APP CST3 SERPINA3
3 protease binding GO:0002020 9.54 CST3 MBP TNF
4 lipoprotein particle binding GO:0071813 9.32 APOE MAPT
5 identical protein binding GO:0042802 9.28 APOE APP BCHE CST3 MAPT NEFL
6 cholinesterase activity GO:0004104 9.26 ACHE BCHE
7 amyloid-beta binding GO:0001540 9.26 ACHE APOE BCHE CST3
8 acetylcholinesterase activity GO:0003990 9.16 ACHE BCHE

Sources for Vascular Dementia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....